SCHEMBL22923302

SCHEMBL22923302

CCc1ccc2c(c1)[C@@H](C)CO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 1/20 0.48
PARP1 P09874 1/20 0.41
HTR2A P28223 1/20 0.40
DRD3 P35462 4/20 0.35
CYP1A2 P05177 4/20 0.35
DRD2 P14416 3/20 0.35
CYP3A4 P08684 3/20 0.35
CYP2D6 P10635 3/20 0.35
CYP2C19 P33261 3/20 0.35
TP53 P04637 3/20 0.35
ALDH1A1 P00352 2/20 0.35
OPRM1 P35372 2/20 0.35
DRD4 P21917 2/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TRPA1 O75762 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13038051 1.00 HCRTR2 (0.48) HCRTR2PARP1HTR2ADRD3CYP1A2
SCHEMBL507239 0.84 HTR2A (0.39) HCRTR2HTR2ADRD3CYP1A2DRD2
SCHEMBL10157958 0.83 HCRTR2 (0.41) HCRTR2PARP1CYP1A2CYP2D6ALDH1A1
SCHEMBL18656431 0.81 HTR2A (0.45) HCRTR2HTR2ACYP3A4CYP2D6ALDH1A1
SCHEMBL6184006 0.81 HTR2A (0.40) HCRTR2HTR2ADRD3CYP1A2DRD2
SCHEMBL9581223 0.78 HCRTR2 (0.43) HCRTR2PARP1DRD3CYP1A2DRD2
SCHEMBL5713612 0.76 HCRTR2 (0.44) HCRTR2PARP1DRD3CYP1A2DRD2
SCHEMBL8278101 0.76 HCRTR2 (0.44) HCRTR2PARP1DRD3CYP1A2DRD2
SCHEMBL8278342 0.76 HCRTR2 (0.44) HCRTR2PARP1DRD3CYP1A2DRD2
SCHEMBL7752945 0.76 HTR1A (0.58) HCRTR2PARP1CYP3A4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210024493-A1 Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity THERAVANCE RESPIRATORY COMPANY, LLC 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024493-A1 Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity ADRB2, ADRB1, ADRA2B HCRTR2 278/4885PARP1 4173/4885HTR2A 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.